Prozone effect of serum IgE levels in a case of plasma cell leukemia
Open Access
- 10 September 2010
- journal article
- case report
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 3 (1) , 32
- https://doi.org/10.1186/1756-8722-3-32
Abstract
We describe a case of multiple myeloma (MM) and secondary plasma cell leukemia (PCL) secreting IgE-kappa immunoglobulin. To our knowledge, only 2 cases of IgE-producing secondary PCL have been reported in the medical literature. In our patient, the only tumor marker available for monitoring the therapeutic response to chemotherapy and allogeneic stem cell transplantation was the quantitative M component at serum protein electrophoresis (SPEP), because serum free light chains were in the normal range, Bence-Jones proteinuria was absent, and quantitative serum IgE levels provided inaccurate and erratic results, due to the prozone effect. This is a laboratory phenomenon that occurs when antigen excess interferes with antibody-based methods requiring immune complex formation for detection. It is important to recognize the presence of a prozone effect, because it can produce falsely normal results, and therefore it could lead clinicians to incorrect assessment of the response to therapy.Keywords
This publication has 24 references indexed in Scilit:
- IgE myeloma with elevated level of serum CA125Journal of Zhejiang University-SCIENCE B, 2009
- Skin Involvement in Immunoglobulin E Multiple MyelomaJournal of Clinical Oncology, 2009
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Hyperviscosity and the prozone effect in multiple myelomaTransfusion, 2008
- Low IgE monoclonal gammopathy level in serum highlights 20‐yr survival in a case of IgE multiple myelomaEuropean Journal of Haematology, 2007
- Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphomaLeukemia & Lymphoma, 2007
- Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variantsBlood, 2003
- IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon‐αAmerican Journal of Hematology, 1994
- A New Case of IgE MyelomaActa Haematologica, 1991
- IgE immunoglobulin.BMJ, 1972